BC Week In Review | May 25, 2009
Clinical News

Elagolix: Phase II data

Follow-up data from the Phase II PETAL trial showed that elagolix sustained safety and efficacy after treatment was stopped. Patients received 150 mg once-daily elagolix, 75 mg twice-daily elagolix or Depo-subQ provera 104 for 24...
BioCentury | Sep 15, 2008
Product Development

The elagolix fix

All marketed endometriosis drugs have problematic side effects, especially when taken long term. Doctors would like to have a drug that can be taken safely over a long period of time, and Neurocrine Biosciences Inc....
BC Week In Review | Sep 8, 2008
Clinical News

Elagolix: Phase II data

In the double-blind, U.S. Phase II PETAL trial in 252 patients with endometriosis, both doses of elagolix met the primary endpoint of reduction in mean BMD from baseline and the secondary efficacy endpoint of improvement...
BC Week In Review | Apr 11, 2005
Clinical News

Depo-subQ provera 104 regulatory update

FDA approved an NDA for Depo-subQ provera 104 medroxyprogesterone acetate injectable suspension to treat pain caused by endometriosis. Pfizer Inc. (PFE), New York, N.Y.   Product: Depo-subQ provera 104   Business: Genitourinary  ...
Items per page:
1 - 4 of 4